U.S. flag

An official website of the United States government

NM_020070.4(IGLL1):c.549C>T (p.Pro183=) AND Agammaglobulinemia 2, autosomal recessive

Germline classification:
Benign (2 submissions)
Last evaluated:
Jan 31, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000527298.18

Allele description

NM_020070.4(IGLL1):c.549C>T (p.Pro183=)

Gene:
IGLL1:immunoglobulin lambda like polypeptide 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
22q11.23
Genomic location:
Preferred name:
NM_020070.4(IGLL1):c.549C>T (p.Pro183=)
HGVS:
  • NC_000022.11:g.23573359G>A
  • NG_009791.1:g.11950C>T
  • NM_001369906.1:c.552C>T
  • NM_020070.4:c.549C>TMANE SELECT
  • NM_152855.3:c.*178C>T
  • NP_001356835.1:p.Pro184=
  • NP_064455.1:p.Pro183=
  • LRG_69:g.11950C>T
  • NC_000022.10:g.23915546G>A
  • NM_020070.3:c.549C>T
  • p.Pro183Pro
Links:
dbSNP: rs75088277
NCBI 1000 Genomes Browser:
rs75088277
Molecular consequence:
  • NM_152855.3:c.*178C>T - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
  • NM_001369906.1:c.552C>T - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_020070.4:c.549C>T - synonymous variant - [Sequence Ontology: SO:0001819]

Condition(s)

Name:
Agammaglobulinemia 2, autosomal recessive (AGM2)
Synonyms:
AGAMMAGLOBULINEMIA, AUTOSOMAL RECESSIVE, DUE TO IGLL1 DEFECT
Identifiers:
MONDO: MONDO:0013287; MedGen: C3150750; OMIM: 613500

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000660410Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Benign
(Jan 31, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV000884030ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
criteria provided, single submitter

(ARUP Molecular Germline Variant Investigation Process 2024)
Benign
(Nov 22, 2023)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV000660410.6

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories, SCV000884030.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Aug 25, 2024